Amylyx Amylyx
Stories About

Amylyx

In college, Amylyx cofounders Josh Cohen and Justin Klee dreamed of finding a treatment for diseases like ALS. When their drug's promise did not pan out, they pulled it voluntarily from the market. Amylyx Pharmaceuticals hide caption

toggle caption
Amylyx Pharmaceuticals

Lots of drug companies talk about putting patients first — but this one actually did

  • <iframe src="https://www.npr.org/player/embed/1251409920/1251419014" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

The drugmaker Amylyx is asking the FDA to approve a new medication for ALS, a fatal neurodegenerative disease. It's possible the agency could greenlight the drug by the end of the month. Manuel Balce Ceneta/AP hide caption

toggle caption
Manuel Balce Ceneta/AP

FDA seems poised to approve a new drug for ALS, but does it work?

  • Download
  • <iframe src="https://www.npr.org/player/embed/1124138839/1124441200" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript